Treatment Information

Back

Melanoma treatment details. Chemotherapy.

Peter MacCallum Cancer Centre, East Melbourne, Australia.

Survival: monthsCountry:Australia
Toxiciy Grade:5City/State/Province:East Melbourne
Treatments:ChemotherapyHospital:Peter MacCallum Cancer Centre
Drugs:Journal:Link
Date:Feb 2014

Description:

Patients:
This phase 3 study involved metastatic melanoma patients with a mutation in the BRAF gene who had not received prior treatment. Patients were divided into two treatment groups. Group A consisted of 337 patients with a median age of 56 years, 59% of whom were male. Group B had 338 patients with a median age of 52.5 years, 54% of whom were male.

Treatment:
Patients in group A were treated with vemurafenib, a biologic therapy agent that is an inhibitor of the BRAF protein.

Patients in group B received chemotherapy with dacarbazine.

Toxicities:
There were eight unspecified grade 5 adverse events reported for group A. Grade 4 neutropenia and liver toxicity were also reported.

There were seven unspecified grade 5 adverse events reported for group B. Grade 4 neutropenia was also reported.

Results:
The median overall survival rates for groups A and B were 13.6 and 9.7 months, respectively.

Support:
This study was supported by Hoffmann-La Roche-Genentech, a pharmaceutical company.

Correspondence: Dr. Grant A McArthur; email: [email protected]



Back